Meds, Mind, Body & Benefits > Questions About Treatment & Side Effects

HIV Medications

<< < (2/3) > >>

Thanks for providing such great info. I recently had my six month check up and my doc had been suggesting I might want to replace my Atripla with a new regimen. Using this website as a resource I spent a lot of time researching. I printed out your chart, looked at the pros/cons of each med, and even brought the chart with me to my doc. She was impressed at my knowledge on all that is available. Long story short, I decided to switch  to Biktarvy

Jim Allen:
Glad the chart helped and, ill pass on the feedback.

Biktarvy - cool, hearing a lot of good things about this combo.

Jim Allen:
Updated with new links to the updated drug charts, 1st of July 2019.

We’ve come a long way since the early years of the HIV/AIDS epidemic. Today, there are safe and effective drugs on the market to treat HIV that are easy to take and have fewer side effects.

Click for a list of approved and experimental HIV medications

Click for a list of approved HIV medications and their dosing info.

Click for a printable version of the POZ 2019 Drug Chart. (updated July 2019)

For information about the specific classes of HIV drugs, links can be found here: hiv-medications

Single-Tablet Regimens
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Protease Inhibitors (PIs)
Integrase Inhibitors
Monoclonal Antibodies
Entry Inhibitors
Pharmacokinetic Enhancers

Anyone looking for information on starting treatment can begin by reading this brief and useful lesson: Starting treatment.

Click for treatment recommendations.

Jim Allen:
December 2019

US - Updated treatment guidelines

An overview of what has changed/been updated

In short:

--- Quote ---Treatment as Prevention

The new guidelines reflect the growing understanding that people on effective antiretroviral treatment who have an undetectable viral load (under 200) do not transmit the virus to their sex partners.  The panel recommends that people starting treatment should use another form of prevention—for example, condoms or PrEP for a partner—for at least the first six months and until they receive an undetectable viral load test result.

First Two-Drug Initial Regimen

Dovato - For the first time, the guidelines include a two-drug combination to the list of recommended regimens for starting treatment; such recommendations were previously limited to three-drug regimens.  The other approved two-drug single-tablet regimen, Juluca (dolutegravir/rilpivirine), is only for people who switch treatment with an undetectable viral load, not for initial therapy.

Rapid Treatment Initiation

The guidelines recommend that antiretroviral therapy should be started immediately or as soon as possible after HIV diagnosis.  For those with acute or recent infection, the panel added Biktarvy (bictegravir/tenofovir alafenamide/emtricitabine) as a recommended option for those who will start treatment before resistance test results are available.

Cost Considerations

The guidelines have an updated section on cost considerations related to antiretroviral treatment, including an overview of the individual and societal costs of HIV care in the United States. A new subsection on cost sharing looks at how cost-containment practices may affect out-of-pocket payments for people with Medicaid, Medicare and AIDS Drug Assistance Program (ADAP) coverage. The section also features a revised discussion about the increased cost of brand-name antiretrovirals and the expected impact of generic regimens as these drugs go off patent.


The tuberculosis section has been updated with new data on short-course regimens for the treatment of latent tuberculosis and new data on drug interactions between antiretrovirals and the TB drugs rifampin and rifapentine.
--- End quote ---

The names are quite funny haha. Dovato is a fusion of Demy Lovato........
I also noticed most of the meds revolve around tenofovir and emtricirabine.


[0] Message Index

[#] Next page

[*] Previous page

Go to full version